Maurer, Marcus http://orcid.org/0000-0002-4121-481X
Magerl, Markus
Aygören-Pürsün, Emel
Bork, Konrad
Farkas, Henriette
Longhurst, Hilary
Kiani‑Alikhan, Sorena
Bouillet, Laurence
Boccon-Gibod, Isabelle
Cancian, Mauro
Zanichelli, Andrea
Launay, David
Funding for this research was provided by:
BioCryst Pharmaceuticals, Inc
Charité - Universitätsmedizin Berlin
Article History
Received: 31 August 2021
Accepted: 26 December 2021
First Online: 13 January 2022
Declarations
:
: This is a retrospective case series with anonymized data, and ethics committee approval is not required. Written informed consent for publication has been provided by all patients, except for one patient who was deceased and for whom consent has been provided by next of kin.
: Written informed consent for publication has been provided by all patients, except for one patient who was deceased and for whom consent has been provided by next of kin.
: All authors received an honorarium for attending the expert meeting described in the Patients and methods section. MMaurer reports grants and/or personal fees from BioCryst Pharmaceuticals, Inc., CSL Behring, Dyax Corp., KalVista Pharmaceuticals, Shire/Takeda, Centogene, Pharming, Alnylam Pharmaceuticals and Pharvaris. MMagerl reports personal fees and/or non-financial support from Shire/Takeda, CSL Behring, Pharming, BioCryst Pharmaceuticals, Inc., KalVista Pharmaceuticals, and Octapharma AG. EAP reports grants, personal fees and/or support for attending meetings and/or travel from CSL Behring, Shire/Takeda, Centogene, Adverum Biotechnologies, BioCryst Pharmaceuticals, BioMarin Pharmaceutical Inc, Kalvista Pharmaceuticals, Pharming and Pharvaris. KB reports grants, and/or personal fees from CSL Behring, Shire/Takeda and Pharvaris. HF reports grants and/or personal fees from CSL Behring, Shire/Takeda, Pharming, BioCryst Pharmaceuticals, Inc. and KalVista Pharmaceuticals. HL reports grants, personal fees and/or non-financial support from BioCryst Pharmaceuticals, Inc., KalVista Pharmaceuticals, CSL Behring, Takeda, gsk, Pharvaris and Pfizer. SK-A reports personal fees from BioCryst Pharmaceuticals, Inc., Takeda and CSL Behring. LB reports no further disclosures. IB-G reports grants, personal fees and/or non-financial support from Takeda, BioCryst Pharmaceuticals, and Pharming. MC reports personal fees from BioCryst Pharmaceuticals, Inc and Kalvista Pharmaceuticals. AZ reports personal fees from CSL Behring, Sobi and Takeda. DL reports grants and personal fees from gsk and Actelion. Professor Launay reports grants, consulting fees and personal fees from BioCryst Pharmaceuticals, CSL Behring, and Shire/Takeda.